41 research outputs found

    Effect of Fibrin-binding Synthetic Oligopeptide on the Healing of Full-thickness Skin Wounds in Streptozotocin-induced Diabetic Rats

    No full text
    Introduction Fibronectin(FN) has many other adhesive sites for various substances, including fibrin, heparin and collagen. The FN subunit contains two fibrin binding sites. Among these two sites, the major site close to the amino terminus serves as a transglutamination site for activated factor XIII, crosslinking FN to various other proteins including fibrin, fibrinogen. In blood clotting cascade, plasma FN-fibrin matrix is covalently cross linked, and then it promotes fibroblast adhesion, spreading, and migration into the clot. However, due to the common shortcomings of whole protein usage, including instability to enzymatic degradation, unexpected effects of other domains, nonspecific binding to other types of cells, difficulty in obtaining a stable attachment, and even integrin blocking effects, small synthetic peptides with active binding sequences of natural proteins have been proposed as alternatives. Based on these findings, we assumed that topical application of fibrin-binding oligopeptides from FN to the soft tissue wound site might compensate the impaired wound healing in diabetes individuals. The aim of this study was to investigate whether topical application of fibrin-binding oligopeptides derived from FN promotes wound healing in streptozotocin (STZ)-induced diabetic rats. Materials and Methods Oligopeptides including fibrin-binding sequences (FF3 : CFDKYTGNTYRV, FF5 : CTSRNRCNDQ) of FN repeats were synthesized based on primary and tertiary human plasma FN structures (FINC-HUMAN: P02751). Each peptide was loaded in 15 x 15 mm fibrous alginate dressings, and the release kinetics of the peptides was evaluated using trinitrobenzene sulfonic acid (TNBSA) for 144 hours. Two full-thickness cutaneous wounds were prepared on the dorsal skin of each 75 diabetes induced rats. Each wound was divided into FF3-loaded alginate dressing group, FF5-loaded alginate dressing group, alginate dressing group and negative control group. Two rats were sacrificed at day 0, and 24 rats were sacrificed at day 3, day 7 and day 14, respectively. The wound closure rate, inflammation degree, expression of TGF-Ξ²1 and hydroxyproline content were evaluated. Results Both FF3 and FF5 peptides were released rapidly within the first 24 hours. Regarding the wound closure rate, FF3-loaded dressing treated wounds closed significantly faster than other wounds at day 3. At day 7, both FF3- & FF5-loaded dressing treated wounds showed more wound closure than the alginate dressing treated group and the negative control group. At day 14, only negative control group showed delayed wound closure over the other groups. And at day 14, FF3- & FF5- loaded dressing treated wounds demonstrated less inflammatory cells infiltration than alginate dressing treated and negative group wounds. TGF-Ξ²1 positive cells were more abundant in FF3-, FF5-treated alginate dressing treated wound than negative control wounds at day 3 and 14. At day 7, FF3- & FF5- treated wounds showed more TGF-Ξ²1 positive cells than in alginate dressing treated wounds and negative control wounds. At last, the hyrdroxyproline contents in the FF3, FF5 group were higher than in the alginate dressing treated group and negative control group at day 7 and day 14. Conclusions Topical application of fibrin-binding domain synthetic oligopeptides from FN resulted in acceleration of full-thickness cutaneous wound healing in diabetic rats. Enhancement of TGF-Ξ²1 expression in fibrin-binding domain synthetic oligopeptides treated wounds seems to be a contributing factor or possible mechanism for the improvement of diabetic skin wound healing.Docto

    λ™μ˜μƒ(Moving Image)의 μ‘°ν˜•μ  νŽΈμ§‘κΈ°λ²• κ°œλ°œμ„ ν†΅ν•œ μž‘ν’ˆ 연ꡬ

    No full text
    ν•™μœ„λ…Όλ¬Έ(석사)--μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› :μ‚°μ—…λ””μžμΈκ³Ό μ‹œκ°λ””μžμΈμ „κ³΅,2000.Maste

    κ³Όν•™ ν™œλ™μ—μ„œμ˜ λͺ¨ν˜•κ³Ό λͺ¨ν˜•ν™” : 전ꡬ κΈ°ν›„ λͺ¨ν˜•μ„ μ€‘μ‹¬μœΌλ‘œ

    No full text
    ν•™μœ„λ…Όλ¬Έ(석사)--μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› :ν˜‘λ™κ³Όμ • 과학사 및 κ³Όν•™μ² ν•™,2002.Maste

    (The) prognostic value of serum CA 125 in endometrial cancer.

    No full text
    μ˜κ³Όν•™μ‚¬μ—…λ‹¨/석사[ν•œκΈ€] μžκΆλ‚΄λ§‰μ•”μ€ λ―Έκ΅­μ—μ„œμ˜ κ°€μž₯ ν”ν•œ λΆ€μΈμ•”μœΌλ‘œ, 1997λ…„ ν•œ ν•΄ λ™μ•ˆ 37,400λͺ…이 μ‹ ν™˜μœΌλ‘œ λ“±λ‘ν•˜μ˜€κ³  6,400λͺ…이 생λͺ…을 μžƒμ€ κ²ƒμœΌλ‘œ 보고 λ˜μ—ˆλ‹€. 우리 λ‚˜λΌμ—μ„œλŠ” μžκΆκ²½λΆ€μ•”μ΄ κ°€μž₯ ν”ν•œ λΆ€μΈμ•”μ΄μ§€λ§Œ, μ„œκ΅¬ν™” λ˜μ–΄ κ°€λŠ” μƒν™œ 양상에 따라 점차 μžκΆλ‚΄λ§‰μ•”μ˜ μ€‘μš”μ„±μ΄ λŒ€λ‘λ˜κ³  μžˆλ‹€. μ’…μ–‘ν‘œμ§€λ¬Όμ§ˆμΈ Cancer Antigen 125 (CA 125)λŠ” κ³ λΆ„μžλŸ‰μ˜ λ‹Ήλ‹¨λ°±μœΌλ‘œ 이루어진 μž₯μ•‘μ„± λ‚œμ†Œμ•” 세포주 OVCA 433에 λŒ€ν•œ 단일 클둠 ν•­μ²΄λ‘œμ„œ, Bast등이 35U/γŽ– λ―Έλ§Œμ„ 정상 λ²”μœ„λ‘œ μ œμ‹œν•œ 이래 이 μΈ‘μ •μΉ˜λ₯Ό κΈ°μ€€μœΌλ‘œ μžκΆλΆ€μ†κΈ° μ’…μ–‘μ˜ μ•…μ„± 유무, 비점앑성 λ‚œμ†Œμ•”μ—μ„œμ˜ μ˜ˆν›„μΈμž, λ˜λŠ” λ‚œμ†Œμ•”μ—μ„œ ν•­μ•”μš”λ²•μ— λŒ€ν•œ λ°˜μ‘μ •λ„λ₯Ό μΈ‘μ •ν•˜κΈ° μœ„ν•˜μ—¬ μ“°μ—¬μ Έ μ™”λ‹€. μžκΆλ‚΄λ§‰μ•”μ—μ„œλŠ” λ‚œμ†Œμ•”μ˜ CA 125처럼 μœ μš©ν•˜κ²Œ 쓰일 수 μžˆλŠ” μ’…μ–‘ν‘œμ§€λ¬Όμ§ˆμ— λŒ€ν•œ 연ꡬ가 λ§Žμ§€ μ•Šλ‹€. 정상 μžκΆλ‚΄λ§‰ 쑰직과 μžκΆλ‚΄λ§‰μ•” 쑰직 λͺ¨λ‘μ—μ„œ CA 125κ°€ λ°œν˜„λœλ‹€λŠ” 보고λ₯Ό 기초둜 λ³Έ μ—°κ΅¬μ—μ„œλŠ” μžκΆλ‚΄λ§‰μ•” ν™˜μžμ˜ 수술 μ „ 평가에 μžˆμ–΄μ„œ CA 125의 의의λ₯Όμ•Œμ•„보고 이에 λŒ€ν•œ μ μ ˆν•œ κΈ°μ€€μΉ˜λ₯Ό μ„€μ •ν•˜κ³ μž ν•˜μ˜€λ‹€. 이상과 같은 λͺ©μ  ν•˜μ— 1995λ…„ 3μ›”λΆ€ν„° 2001λ…„ 3μ›”κΉŒμ§€ μ—°μ„ΈλŒ€ν•™κ΅ μ˜κ³ΌλŒ€ν•™ μ‚°λΆ€μΈκ³Όμ—μ„œ μžκΆλ‚΄λ§‰μ•”μœΌλ‘œ 진단 λ°›μ•„ 수술적 병기 결정을 ν•˜κ³  이후 좔적관찰 쀑인 119λͺ…μ˜ ν™˜μžλ“€μ˜ μ˜λ¬΄κΈ°λ‘μ„ 기초둜 ν›„ν–₯적 연ꡬλ₯Ό μ‹œν–‰ ν•˜μ˜€λ‹€. CA 125의 μ˜ˆν›„μΈμžλ‘œμ„œμ˜ κ°€μΉ˜λŠ” λ‹€λ₯Έ μ˜ˆν›„μΈμžλ“€κ³Όμ˜ μ—°κ΄€μ„±, μˆ˜μˆ μ†Œκ²¬μ˜ μ˜ˆμΈ‘μ •λ„, 5λ…„ 생쑴λ₯  등을 ν†΅ν•˜μ—¬ ν‰κ°€ν•˜μ˜€μœΌλ©°, κ·Έ κΈ°μ€€μΉ˜λŠ” 기쑴에 μ•Œλ €μ Έ μžˆλŠ” 35U/γŽ–, λ˜λŠ” 20U/γŽ–λ₯Ό 근거둜 각각의 민감도, νŠΉμ΄λ„, μœ„μŒμ„±λ₯ , μœ„μ–‘μ„±λ₯ μ„ κ΅¬ν•˜μ—¬ λΆ„μ„ν•˜μ˜€λ‹€. ν™˜μžμ˜ 혈청 CA 125λŠ” νš¨μ†Œ λ©΄μ—­ 뢄석 방법 (enzyme immunoassay; Elecsys 2010, Roche Ltd., Basel, Switzerland)을 이용 ν•˜μ˜€λ‹€. 연ꡬ κ²°κ³Ό μžκΆλ‚΄λ§‰μ•”μ—μ„œ CA 125λŠ” λΆˆλŸ‰ν•œ μž„μƒλ³‘λ¦¬ν•™μ  μ˜ˆν›„μΈμžμΈ μ§„ν–‰λœ 병기, 자ꢁ근측 λ˜λŠ” μžκΆκ²½λΆ€ μΉ¨λ²”, λ‚˜μœ 쑰직학적 뢄화도와 연관이 μžˆλŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬μœΌλ©°(p<0.05), 수술 μ†Œκ²¬μ„ μ˜ˆμΈ‘ν•  수 μžˆλŠ” 수술 μ „ 검사항λͺ©μœΌλ‘œλŠ” 자기곡λͺ…μ΄¬μ˜, 혈청 CA 125, μ§ˆμ΄ˆμŒνŒŒκ°€ μžˆμ—ˆκ³ , CA 125β‰₯20U/γŽ–κ°€ 민감도와 μœ„μŒμ„±λ₯  μΈ‘λ©΄μ—μ„œ λ³Ό λ•Œ 기쑴의 κΈ°μ€€μΉ˜μΈ CA 125β‰₯35U/γŽ– 보닀 더 μ˜λ―Έκ°€ μžˆμ—ˆκ³ , CA 125β‰₯20U/γŽ–λŠ” 5λ…„ 생쑴λ₯ κ³Ό μœ μ˜ν•œ 관계λ₯Ό λ³΄μ˜€λ‹€(p<0.05). μžκΆλ‚΄λ§‰μ•”μ—μ„œ CA 125λŠ” μ˜ˆν›„μΈμžλ‘œμ„œμ˜ μž„μƒμ  κ°€μΉ˜κ°€ μžˆμœΌλ―€λ‘œ 기초 검사에 이λ₯Ό ν¬ν•¨μ‹œμΌœ ν™˜μžμ˜ μ˜ˆν›„λ₯Ό μ˜ˆμΈ‘ν•˜κ³  치료 방법을 κ°œλ³„ν™”ν•˜λŠ”λ° μ΄μš©ν•  수 μžˆκ² λ‹€. 특히 폐경 여성이 λŒ€λ‹€μˆ˜μΈ μžκΆλ‚΄λ§‰μ•”μ—μ„œλŠ” 혈청 CA 125κ°€ 기쑴의 35U/γŽ–κ°€ μ•„λ‹Œ 20U/γŽ– μ΄μƒμœΌλ‘œμΈ‘μ •λ˜μ—ˆμ„ λ•Œλ₯Ό 의미 있게 μ¦κ°€λœ κ²ƒμœΌλ‘œ κ°„μ£Όν•˜μ—¬μ•Όκ² λ‹€. μžκΆλ‚΄λ§‰μ•”μ—μ„œ μΆ”μ μΈμžλ‘œμ„œμ˜ CA 125의 κ°€μΉ˜λŠ” 더 λ§Žμ€ ν™˜μžλ“€μ„ λŒ€μƒμœΌλ‘œ μ—°κ΅¬λ˜μ–΄μ Έμ•Όν•  κ²ƒμœΌλ‘œ μ‚¬λ£Œλœλ‹€. [영문] Endometrial cancer is the most common gynecologic cancer in the United States, and in the year 1997, about 37,400 patients were newly registered in the cancer registry and 6,400 patients died due to this disease. In Korea, the most common gynecologic cancer is still the uterine cervix cancer, but the incidence of endometrial cancer is rising with the changes in life style and there is a growing academic interest about this disease. The tumor marker Cancer Antigen 125 (CA 125) is a monoclonal antibody towards the serous ovarian cancer cell line OVCA 433. Since the first report by Bast et al. on CA 125, it has been used as the marker of adnexal tumor, the prognostic factor of nonmucinous ovarian malignancy, and the follow up marker of ovarian malignancy during chemotherapy. Unlike ovarian malignancy, not many studies have been undertaken about the significance of tumor markers in endometrial cancer. As it has been reported, CA 125 is found in normal and malignant endometrium. Based on these reports, the prognostic value of serum CA 125 sampled before the staging operation and the right CA 125 cut-off level in endometrial cancer was evaluated. Enzyme immunoassay (Elecsys 2010; Roche Ltd., Basel, Switzerland) was used for the measurement of serum CA 125. Medical charts of 119 endometrial cancer patients diagnosed and surgically treated at the Department of Obstetrics and Gynecology, Yonsei University College of Medicine from March 1995 to March 2001 were reviewed. The prognostic value of CA 125 was evaluated by comparing it to other established prognostic factors of endometrial cancer such as myometrial invasion, cervix extension, tumor size, and grossly invasive disease. Informations that could be obtained prior to the surgical staging procedure such as magnetic resonance imaging, transvaginal ultrasonography, CA 125 level, histologic grade, and age were evaluated for their predictability of surgical findings suggesting extensive endometrial cancer needing lymphadenectomy. The difference of five year survival according to the level of CA 125 was also evaluated. The right cut-off value of CA 125 in the endometrial cancer patients who were mostly postmenopausal women was estimated. The result of this study implies that the level of presurgically taken serum CA 125 level correlated well with the established prognostic factors of endometrial cancer. CA 125 was one of the information that could be obtained prior to the surgical staging for predicting extensive endometrial cancer, and it could be correlated with the 5 year survival. CA 125β‰₯20U/γŽ– had a higher sensitivity and lower false negative rate in predicting extensive endometrial cancer compared to the conventionally used level of CA 125β‰₯35U/γŽ–. CA 125 has a prognostic value in predicting the extensive endometrial cancer needing lymphadenectomy. It might be included in the baseline study of endometrial cancer for predicting the prognosis and individualizing the treatment modality. CA 125β‰₯20U/γŽ– might be considered as the cut-off level in endometrial cancer for a better sensitivity and false negative rate. The significance of CA 125 as a follow up marker in endometrial cancer awaits further studies in the future.ope

    Muscle regeneration with tooth-derived primary culture cells

    No full text
    μΉ˜μ˜ν•™κ³Ό/석사본 μ—°κ΅¬λŠ” κ΅μ •μΉ˜λ£Œ μ‹œ λ°œκ±°λ˜λŠ” 영ꡬ μ†Œκ΅¬μΉ˜μ˜ 일차 λ°°μ–‘ 세포λ₯Ό μ΄μš©ν•˜μ—¬ κ·Όμœ‘μ„Έν¬λ‘œμ˜ λΆ„ν™”λ₯Ό μœ λ„ν•˜κ³ , 이λ₯Ό 마우슀 생체내에 μ μš©ν•˜μ—¬ 근윑 μž¬μƒ 효과λ₯Ό μ•Œμ•„λ³΄κ³ μž ν•˜μ˜€λ‹€. 발치된 μ†Œκ΅¬μΉ˜μ˜ μΉ˜μ£ΌμΈλŒ€ 및 치수 μ‘°μ§μœΌλ‘œλΆ€ν„° νšλ“ν•œ 세포λ₯Ό DNA νƒˆλ©”ν‹Έν™” 약물인 5-aza-2Β΄-deoxycytidine둜 μ²˜λ¦¬ν•œ ν›„ κ·Όμœ‘μ„Έν¬ λΆ„ν™” μœ λ„λ₯Ό ν™•μΈν•˜μ˜€λ‹€. 마우슀 근윑 손상 및 μž¬μƒ λͺ¨λΈμ„ μ΄μš©ν•˜μ—¬ κ·Όμœ‘μ„Έν¬λ‘œ λΆ„ν™” μœ λ„λœ μΉ˜μˆ˜μ„Έν¬λ₯Ό μž₯딴지근과 ꡐ근에 μ΄μ‹ν•œ ν›„ μ‘°μ§ν•™μ μœΌλ‘œ ν‰κ°€ν•˜κ³ , μ΄μ‹λœ 치수 세포λ₯Ό μΆ”μ ν•œ κ²°κ³Ό λ‹€μŒκ³Ό 같은 결둠을 μ–»μ—ˆλ‹€.1. μΉ˜μ£ΌμΈλŒ€ 및 μΉ˜μˆ˜μ„Έν¬λŠ” κ·Όμœ‘λΆ„ν™” μœ λ„ 배지 λ‹¨λ…μœΌλ‘œλŠ” κ·Όμœ‘μ„Έν¬ λΆ„ν™” μœ λ„κ°€ λ˜μ§€ μ•Šμ•˜μœΌλ‚˜, 5-aza-2Β΄-deoxycytidine μ „ μ²˜λ¦¬μ™€ κ·Όμœ‘λΆ„ν™” μœ λ„ 배지λ₯Ό μ‚¬μš©ν•¨μœΌλ‘œμ¨ 근윑 특이 λ‹¨λ°±μ§ˆμΈ desmin μ–‘μ„±μ˜ myotube ꡬ쑰둜 λΆ„ν™”λ˜μ—ˆλ‹€. μΉ˜μ£ΌμΈλŒ€μ„Έν¬μ— λΉ„ν•΄ μΉ˜μˆ˜μ„Έν¬μ—μ„œ 더 κ΅΅κ³  λ§Žμ€ μ–‘μ˜ myotubeκ°€ λΆ„ν™”λ˜μ—ˆλ‹€.2. μΉ˜μˆ˜μ„Έν¬λŠ” 5-aza-2Β΄-deoxycytidine μ „ 처리둜 κ·Όμœ‘λΆ„ν™” μœ λ„ ν›„ desmin 및 myogenin λ°œν˜„μ΄ μ¦κ°€ν•œ 반면, μΉ˜μ£ΌμΈλŒ€ μ„Έν¬μ—μ„œλŠ” 근윑 λΆ„ν™” μœ λ„ ν›„ myogenin의 λ°œν˜„μ€ 였히렀 κ°μ†Œν•˜μ˜€λ‹€.3. 마우슀 근윑 μž¬μƒ λͺ¨λΈμ˜ H&E (hematoxylin and eosin) 염색 κ²°κ³Ό, κ·Όμœ‘λΆ„ν™” μœ λ„λœ μΉ˜μˆ˜μ„Έν¬λ₯Ό μ£Όμž…ν•œ ꡰ의 경우 λŒ€μ‘°κ΅°μ— λΉ„ν•΄ μ‘°μ§ν•™μ μœΌλ‘œ κ·Όμœ‘μž¬μƒ νš¨κ³Όκ°€ 있음이 ν™•μΈλ˜μ—ˆλ‹€.4. 마우슀 근윑 μž¬μƒ λͺ¨λΈμ„ μ΄μš©ν•˜μ—¬ μž₯딴지근에 μ£Όμž…λœ μΉ˜μˆ˜μ„Έν¬λ₯Ό μΆ”μ ν•œ κ²°κ³Ό 마우슀 근윑 쑰직으둜의 생착이 ν™•μΈλ˜μ—ˆλ‹€.5. 마우슀 근윑 μž¬μƒ λͺ¨λΈμ˜ λ©΄μ—­ν˜•κ΄‘ 뢄석 κ²°κ³Ό, κ·Όμœ‘λΆ„ν™” μœ λ„λœ μΉ˜μˆ˜μ„Έν¬λ₯Ό μ£Όμž…ν•œ ꡰ의 경우, PBSλ₯Ό μ£Όμž…ν•œ λŒ€μ‘°κ΅°μ— λΉ„ν•΄ 손상 μ‹œ μž¬μƒλ˜λŠ” μ‹ μƒκ·Όμœ‘μ˜ ν‘œμ§€μžμΈ eMHC (embryonic myosin Heavy chain) 및 ν˜ˆκ΄€λ‚΄ν”Όμ„Έν¬ ν‘œμ§€μžμΈ CD31 λ°œν˜„μ΄ μš°μ„Έν•˜μ˜€λ‹€.λ”°λΌμ„œ μΉ˜μˆ˜μ„Έν¬λ₯Ό μ΄μš©ν•œ 생체 λ‚΄ 이식 연ꡬ가 μΆ©λΆ„νžˆ λ’·λ°›μΉ¨ λœλ‹€λ©΄ μ•…μ•ˆλ©΄ 연쑰직 μž¬μƒ 뢄야에 λŒ€ν•œ ν™œμš© κ°€λŠ₯성을 κΈ°λŒ€ν•  수 μžˆμ„ 것이닀.ope

    λ‹¬λΌν”Όμ½œλΌμ˜ Canti di prigionia에 κ΄€ν•œ 뢄석 및 κ³ μ°°

    No full text
    ν•™μœ„λ…Όλ¬Έ(석사)--μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› :μŒμ•…κ³Ό μž‘κ³‘μ „κ³΅,1995.Maste

    Effect of non-surgical therapy combined with overhanging margin removal by Profin system in chronic periodontitis patient

    No full text
    Thesis(masters) --μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› :μΉ˜μ˜ν•™κ³Ό(μΉ˜μ£Όκ³Όν•™μ „κ³΅),2008. 8.Maste

    The Study on men`s jacket block according to somatotype

    No full text
    ν•™μœ„λ…Όλ¬Έ(박사)--μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› :의λ₯˜ν•™κ³Ό,2000.Docto

    Study on regulaatorygenes controlling flowering time in Capsicum annuum L.

    No full text
    Maste
    corecore